Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03089645
Title MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

Advanced Solid Tumor

Therapies

MEDI5083

Durvalumab + MEDI5083

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.